ArticleBreast cancer research : BCR2011
Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.
Article in Breast cancer research : BCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 94 citations in OpenAlex.
- An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter.International journal of molecular sciences · 2023Article
- Tumor matrix stiffness provides fertile soil for cancer stem cells.Cancer cell international · 2023Review
- Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor.International journal of molecular sciences · 2021Article
- Peptidylarginine Deiminase IV Regulates Breast Cancer Stem Cells via a Novel Tumor Cell-Autonomous Suppressor Role.Cancer research · 2020Article
- Article
- Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features.Journal of Cancer · 2020Article
- Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survival.Journal of the Egyptian National Cancer Institute · 2019Article
- ERα is required for suppressing OCT4-induced proliferation of breast cancer cells via DNMT1/ISL1/ERK axis.Cell proliferation · 2019Article
- Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.Cell death & disease · 2019Article
- OCT4B mediates hypoxia-induced cancer dissemination.Oncogene · 2019Article
- Reprogramming factors induce proliferation and inhibit apoptosis of melanoma cells by changing the expression of particular genes.Molecular medicine reports · 2019Article
- The dualistic origin of human tumors.Seminars in cancer biology · 2018Review
- Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.BMC cancer · 2018Article
- EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.Oncogene · 2018Article
- Aggressive Phenotype of Cells Disseminated via Hematogenous and Lymphatic Route in Breast Cancer Patients.Translational oncology · 2018Article
- BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma.Cancer medicine · 2017Article
- Distinctive expression pattern of OCT4 variants in different types of breast cancer.Cancer biomarkers : section A of Disease markers · 2017Article
- Reprogramming Factors Remodel Melanoma Cell Phenotype by Changing Stat3 Expression.International journal of medical sciences · 2017Article
- JNK/SAPK Signaling Is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells.Stem cells (Dayton, Ohio) · 2016Article
- Acquisition of tumorigenic potential and enhancement of angiogenesis in pulmonary stem/progenitor cells through Oct-4 hyperexpression.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionTumor-initiating cells (TIC) are being extensively studied for their role in tumor etiology, maintenance and resistance to treatment. The isolation of TICs has been limited by the scarcity of this population in the tissue of origin and because the molecular signatures that characterize these cells are not well understood. Herein, we describe the generation of TIC-like cell lines by ectopic expression of the OCT4 transcription factor (TF) in primary breast cell preparations.
methodsOCT4 cDNA was over-expressed in four different primary human mammary epithelial (HMEC) breast cell preparations from reduction mammoplasty donors. OCT4-transduced breast cells (OTBCs) generated colonies (frequency ~0.01%) in self-renewal conditions (feeder cultures in human embryonic stem cell media). Differentiation assays, immunofluorescence, immunohistochemistry, and flow cytometry were performed to investigate the cell of origin of OTBCs. Serial dilutions of OTBCs were injected in nude mice to address their tumorigenic capabilities. Gene expression microarrays were performed in OTBCs, and the role of downstream targets of OCT4 in maintaining self-renewal was investigated by knock-down experiments.
resultsOTBCs overcame senescence, overexpressed telomerase, and down-regulated p16INK4A. In differentiation conditions, OTBCs generated populations of both myoepithelial and luminal cells at low frequency, suggesting that the cell of origin of some OTBCs was a bi-potent stem cell. Injection of OTBCs in nude mice generated poorly differentiated breast carcinomas with colonization capabilities. Gene expression microarrays of OTBC lines revealed a gene signature that was over-represented in the claudin-low molecular subtype of breast cancer. Lastly, siRNA-mediated knockdown of OCT4 or downstream embryonic targets of OCT4, such as NANOG and ZIC1, suppressed the ability of OTBCs to self-renew.
conclusionsTransduction of OCT4 in normal breast preparations led to the generation of cell lines possessing tumor-initiating and colonization capabilities. These cells developed high-grade, poorly differentiated breast carcinomas in nude mice. Genome-wide analysis of OTBCs outlined an embryonic TF circuitry that could be operative in TICs, resulting in up-regulation of oncogenes and loss of tumor suppressive functions. These OTBCs represent a patient-specific model system for the discovery of novel oncogenic targets in claudin-low tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.